Foxx Development (NASDAQ:FOXX) CTO James Liao Sells 9,716 Shares

Foxx Development Holdings Inc. (NASDAQ:FOXX) CTO James Liao sold 9,716 shares of Foxx Development stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $4.61, for a total value of $44,790.76. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Foxx Development Price Performance

Shares of FOXX traded down $0.10 during midday trading on Tuesday, reaching $4.16. The stock had a trading volume of 7,409 shares, compared to its average volume of 12,207. The company has a market capitalization of $29.17 million, a P/E ratio of -1.84 and a beta of -0.28. The firm’s 50 day moving average price is $4.58 and its 200-day moving average price is $4.53. Foxx Development Holdings Inc. has a 52 week low of $1.71 and a 52 week high of $8.88.

Foxx Development (NASDAQ:FOXX) last announced its earnings results on Friday, February 13th. The company reported ($0.62) earnings per share for the quarter. The company had revenue of $16.72 million during the quarter.

Hedge Funds Weigh In On Foxx Development

A hedge fund recently raised its stake in Foxx Development stock. JPMorgan Chase & Co. lifted its position in Foxx Development Holdings Inc. (NASDAQ:FOXX) by 170.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,947 shares of the company’s stock after acquiring an additional 3,121 shares during the period. JPMorgan Chase & Co. owned about 0.07% of Foxx Development worth $27,000 as of its most recent SEC filing. 60.44% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Foxx Development in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Foxx Development

Foxx Development, Inc (NASDAQ: FOXX) operates as a contract manufacturer specializing in the design, assembly and distribution of medical devices and components. The company’s core business centers on phlebotomy and blood collection products, serving clinical laboratories, hospitals and diagnostic testing facilities. Its product portfolio includes evacuated blood collection tubes, safety-engineered winged blood collection sets, syringes and ancillary devices used in specimen collection and handling.

Founded in North Carolina, Foxx Development maintains a manufacturing and distribution campus in Apex, where it integrates engineering, quality control and regulatory compliance under one roof.